Cisplatin has been the most extensively investigated concurrent chemotherapy agent for more than 50 years, due to its radio-sensitizing role. The most commonly used cisplatin dose and schedule is 70-100mg/m2 every 3 weeks, but weekly regimens had also been well studied. 30mg weekly have been used with IMRT in an attempt to reduce toxicities.; alternative protocols like weekly 40 mg/m2 have been used. Weekly cisplatin 40 mg.m2 is listed by NCCN, Head and Neck, SYST-A, 1/6
Traynor AM, Richards GM, Hartig GK, et al. Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck. 2010;32(5):599606. doi:10.1002/hed.21224
Merlotti A, Alterio D, Vigna-Taglianti R, et al. Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology – head and neck working group. Radiat Oncol. 2014;9:264. Published 2014 Dec 29.
N.Osman et al, Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience.Eur Arch Otorhinolaryngol. 2014 Aug;271(8):2253-9.